Inventor · disambiguated record
Mauro Marigo
Also filed as: MARIGO MAURO
42 granted patents·13 pending applications·124 citations·filing 2005–2024
97Inventor score
Top patents by PatentIndex Score
55 records- 0197US11026923B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Jun 8, 2021·4 cites·17 claims
- 0297US11026924B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Jun 8, 2021·4 cites·19 claims
- 0396US10351561B2Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitorsH LUNDBECK AS·Filed 2017·Granted Jul 16, 2019·12 cites·21 claims
- 0495US11111290B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Sep 7, 2021·6 cites·9 claims
- 0595US10806718B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2019·Granted Oct 20, 2020·7 cites·16 claims
- 0694US10034861B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2017·Granted Jul 31, 2018·13 cites·28 claims
- 0794US9346797B12-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsLUNDBECK & CO AS H·Filed 2015·Granted May 24, 2016·7 cites·19 claims
- 0893US11491140B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2020·Granted Nov 8, 2022·2 cites·20 claims
- 0993US10689379B2Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitorsH LUNDBECK AS·Filed 2019·Granted Jun 23, 2020·6 cites·14 claims
- 1093US10618913B2Macrocycles as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Apr 14, 2020·7 cites·19 claims
- 1193US10512632B21 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Dec 24, 2019·9 cites·13 claims
- 1292US10647762B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted May 12, 2020·5 cites·3 claims
- 1391US10766893B21H-pyrazolo[4,3-b]pyridines as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Sep 8, 2020·6 cites·19 claims
- 1490US9353084B22-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's diseaseLUNDBECK & CO AS H·Filed 2015·Granted May 31, 2016·9 cites·22 claims
- 1589US11844755B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2022·Granted Dec 19, 2023·1 cites·12 claims
- 1689US10487142B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2019·Granted Nov 26, 2019·5 cites·3 claims
- 1788US10538525B21,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Jan 21, 2020·5 cites·15 claims
- 1888US10472415B2Antibodies specific for hyperphosphorylated tau and methods of useH LUNDBECK AS·Filed 2017·Granted Nov 12, 2019·5 cites·3 claims
- 1988US2025257124A1Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2024·Application pending·0 cites
- 2085US11104680B21,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitorsH LUNDBECK AS·Filed 2019·Granted Aug 31, 2021·1 cites·15 claims
- 2182US11541039B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Granted Jan 3, 2023·1 cites·24 claims
- 2282US11358971B2Prodrugs of modulators of the NMDA receptorH LUNDBECK AS·Filed 2020·Granted Jun 14, 2022·1 cites·36 claims
- 2378US12129289B2Antibodies specific for hyperphosphorylated tau and methods of use thereofH LUNDBECK AS·Filed 2021·Granted Oct 29, 2024·0 cites·15 claims
- 2478US10045974B22-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsH LUNDBECK AS·Filed 2015·Granted Aug 14, 2018·1 cites·3 claims
- 2573US2020375950A11h-pyrazolo[4,3-b]pyridines as pde1 inhibitorsH LUNDBECK AS·Filed 2020·Application pending·0 cites
- 2672US11535611B2Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Dec 27, 2022·1 cites·9 claims
- 2772US10603310B22-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsH LUNDBECK AS·Filed 2018·Granted Mar 31, 2020·0 cites·3 claims
- 2871US10011596B22-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsH LUNDBECK AS·Filed 2016·Granted Jul 3, 2018·1 cites·31 claims
- 2970US10004738B2Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridinesH LUNDBECK AS·Filed 2016·Granted Jun 26, 2018·1 cites·22 claims
- 3070US8501795B2(3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivativesPUESCHL ASK·Filed 2010·Granted Aug 6, 2013·2 cites·25 claims
- 3169US10059669B22-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's diseaseH LUNDBECK AS·Filed 2015·Granted Aug 28, 2018·1 cites·18 claims
- 3269US10058540B22-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsH LUNDBECK AS·Filed 2015·Granted Aug 28, 2018·1 cites·15 claims
- 3367US9062060B2Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitorsLUNDBECK & CO AS H·Filed 2014·Granted Jun 23, 2015·0 cites·16 claims
- 3464US2022213117A1Prodrugs of modulators of the nmda receptorH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 3562US12195452B2N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2025·0 cites·19 claims
- 3662US8552045B2Tricyclic imidazole compounds as PDE10 inhibitorsKEHLER JAN·Filed 2011·Granted Oct 8, 2013·0 cites·15 claims
- 3761US2024400537A1Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivativesGRUENENTHAL GMBH·Filed 2024·Application pending·0 cites
- 3860US8796304B2Tricyclic imidazole compounds as PDE10 inhibitorsLUNDBECK & CO AS H·Filed 2013·Granted Aug 5, 2014·0 cites·11 claims
- 3956US2024252473A1Sulfoximines as inhibitors of NaV1.8GRUENENTHAL GMBH·Filed 2023·Application pending·0 cites
- 4054US2023365545A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4153US2017291901A11,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 InhibitorsH LUNDBECK AS·Filed 2017·Application pending·0 cites
- 4252US11466027B2Modulators of the NMDA receptorH LUNDBECK AS·Filed 2020·Granted Oct 11, 2022·0 cites·19 claims
- 4351US11634416B2Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridinesH LUNDBECK AS·Filed 2018·Granted Apr 25, 2023·0 cites·15 claims
- 4450US8927738B22-arylimidazole derivatives as PDE10A enzyme inhibitorsLUNDBECK & CO AS H·Filed 2013·Granted Jan 6, 2015·0 cites·7 claims
- 4550US8785653B2(3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivativesLUNDBECK & CO AS H·Filed 2013·Granted Jul 22, 2014·0 cites·10 claims
- 4649US2023322749A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4746US11851425B2Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridinesH LUNDBECK AS·Filed 2018·Granted Dec 26, 2023·0 cites·15 claims
- 4845US9669029B2Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitorsH LUNDBECK AS·Filed 2015·Granted Jun 6, 2017·0 cites·13 claims
- 4943US8501797B2(2-aryl-1H-imidazol-4-yl)-linked heterocycle derivativesPUESCHL ASK·Filed 2010·Granted Aug 6, 2013·0 cites·25 claims
- 5043US2022089547A1Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →